Vunakizumab (IL-17A inhibitor)
Phase 3Small molecule
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Vunakizumab (IL-17A inhibitor) is one of 146 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
145
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
140 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Vepesid
AAvyxa
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Lynparza
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus1 trial
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details